Bibliography
- European parliament and council of the European communities. Decision no. 1295/1999/EC of the European parliament and of the council of 29 April 1999 adopting a programme of community action on rare diseases within the framework for action in the field of public health (1999–2003); 1999
- Gatta G, van der Zwan JM, Casali PG, et al.; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011;47:2493-511
- U.S. Food & Drug Administration (FDA). Developing products for rare diseases & conditions. Available from: http://www.fda.gov/orphan/oda.htm [Accessed 27 January 2014]
- Rare cancers Australia. Available from: http://www.rarecancers.org.au/page/14/understanding-rare-cancers [Accessed 27 January 2014]
- Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 2009;27:3148-53
- Mauer M, Collette L, Bogaerts J, et al. Adaptive designs at European Organi for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size. Eur J Cancer 2012;48:1386-91
- Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol 2010;29:606-9
- Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5:S260-5
- French public heath law (Code de la santé publique) - art. L5121-12. Available from: http://www.legifrance.gouv.fr/affichCodeArticle.do?cidTexte=LEGITEXT000006072665&idArticle=LEGIARTI000025086118&dateTexte=&categorieLien=cid [Accessed 27 January 2014]
- French law N° 2011-2012 of 29th December 2011 – art.18. Available from: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000025053440&dateTexte&categorieLien=id [Accessed 27 January 2014]
- French decree n° 2012-742 of 9th of May 2012. Available from: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000025836838&dateTexte=&categorieLien=id [Accessed 27 January 2014]
- U.S. Food & Drug Administration (FDA). Available from: http://www.fda.gov [Accessed 27 January 2014]
- European Medicines Agency. Available from: http://www.ema.europa.eu [Accessed 27 January 2014]
- Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366:2189-97
- Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011;22:1054-61